Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vericel (VCEL) will present at the Stephens Annual Investment Conference on November 18, 2026, at 4:30 p.m. ET.
The presentation time is 3:30 p.m. CT. A webcast will be available through the Investor Relations section of Vericel’s website at http://investors.vcel.com.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Stephens Annual Investment Conference at 4:30 p.m. ET (3:30 p.m. CT) on Wednesday, November 18, 2026.
A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel®, MACI® and MACI Arthro® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2026 Vericel Corporation. All rights reserved.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
